Is it Time to Dump Your Shares of Moderna?
After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune. The coronavirus vaccine maker has seen revenue plummet as demand for this flagship product -- Moderna's first to be approved -- has slipped. As a result, the stock fell out of favor with investors, leading to a decline of about 80% over the past three years.Since that time, the biotech company has delivered positive news, from the approval of a second product -- its respiratory syncytial virus (RSV) vaccine -- to the approval of updated coronavirus vaccines and progress on cost cuts. Moderna also has an impressive late-stage pipeline and goals for potential product launches on the horizon. Yet none of these elements has been enough to pull the stock out of the doldrums.Considering this, is it time to dump your shares of Moderna? Let's find out.Continue reading
After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune. The coronavirus vaccine maker has seen revenue plummet as demand for this flagship product -- Moderna's first to be approved -- has slipped. As a result, the stock fell out of favor with investors, leading to a decline of about 80% over the past three years.
Since that time, the biotech company has delivered positive news, from the approval of a second product -- its respiratory syncytial virus (RSV) vaccine -- to the approval of updated coronavirus vaccines and progress on cost cuts. Moderna also has an impressive late-stage pipeline and goals for potential product launches on the horizon. Yet none of these elements has been enough to pull the stock out of the doldrums.
Considering this, is it time to dump your shares of Moderna? Let's find out.
